Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.A phase II/III trial of Javelin Pharmaceuticals' drug Dyloject in 155 patients with moderate-to-severe post-surgical pain has suggested that the drug may be more effective in the indication than Voltarol.
Subscribe to our email newsletter
According to Javelin Pharmaceuticals, Dyloject demonstrated total pain relief over four hours, with statistically significant superior pain relief over the first two hours compared to Voltarol.
In the study, Dyloject demonstrated faster onset of analgesia compared to Voltarol according to pain intensity and pain relief measures, and patients who received Dyloject also had a lower incidence and severity of inflammation at the site of intravenous administration compared to those given Voltarol.
“Dyloject was less irritating to veins than Voltarol, which translates into convenience and cost savings for postoperative patients whose intravenous sites risk being inflamed or clotted,” said Dr Daniel Carr, CEO and chief medical officer of Javelin Pharmaceuticals.
“With growing concerns about the safety of selective COX-2 inhibitors, the nonselective non-steroidal anti-inflammatory drug Dyloject is a promising alternative based upon an active pharmaceutical ingredient with a large and well-established safety database.”